Sold as Talacen. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 15, 2026, FDA lists 3 applications for Acetaminophen; Pentazocine Hydrochloride (sold as Talacen), first approved Sep 23, 1982, with 0 new uses approved and 0 published complete response letters.
| Sep 23, 1982 | TalacenNDA 18458 ยท New combination | Sanofi Aventis US | 14 | Discontinued |
| Mar 24, 2000 | Acetaminophen And Pentazocine HydrochlorideANDA 74699 | Watson Labs | 4 | Discontinued |
| Aug 2, 2002 | Acetaminophen And Pentazocine HydrochlorideANDA 76202 | Gavis Pharms | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA